Nuvo Research (NRI-T) Stock Predictions - Stockchase
WATCH LIST
8
Nuvo Research (NRI-T)

ON STOCKCHASE SINCE Mar 2006

Pharma & Healthcare

Nuvo Research

NRI-T

7 watching          
Join the Discussion

Nuvo Research (NRI-T) SAVE Mar, 18, 2019, 12:31 pm

2.45 0.1 (4.26%)

What the experts are saying about NRI-T



  • All
  • Filtered
Signal Opinion Expert
PAST TOP PICK
Nuvo Research(NRI-T) 

December 2, 2016

(A Top Pick Oct 8/15. Up 18.06%.) A nice little company he discovered a few years ago. They had a big fight with their US distributor, and won $50 million. They got a new distribution for their topical cream and it took off. Had a bad 3rd quarter. They have a ton of cash, so there is room for M&A and new products.

Pharma & Healthcare
0 0 0 0 0
0 comments

(A Top Pick Oct 8/15. Up 18.06%.) A nice little company he discovered a few years ago. They had a big fight with their US distributor, and won $50 million. They got a new distribution for their topical cream and it took off. Had a bad 3rd quarter. They have a ton of cash, so there is room for M&A and new products.

Pharma & Healthcare
0 0 0 0 0
0 comments
Fabrice Taylor

Publisher, The President's Club...

Price Price
$5.640
Owned Owned
Yes

COMMENT
Nuvo Research(NRI-T) 

December 4, 2015

Has been involved in this name for about 1.5 years and has done well on it. They have 2 sides to their business. One produces a topical drug called Pennsaid, which is licensed to do sales in the US. The other side is that they are developing drugs, particularly in allergies. The stock plunged from $10-$5 because they had negative results. They have $50 million in cash. He likes this company.

Pharma & Healthcare
0 0 0 0 0
0 comments

Has been involved in this name for about 1.5 years and has done well on it. They have 2 sides to their business. One produces a topical drug called Pennsaid, which is licensed to do sales in the US. The other side is that they are developing drugs, particularly in allergies. The stock plunged from $10-$5 because they had negative results. They have $50 million in cash. He likes this company.

Pharma & Healthcare
0 0 0 0 0
0 comments
Fabrice Taylor

Publisher, The President's Club...

Price Price
$6.690
Owned Owned
Yes

TOP PICK
Nuvo Research(NRI-T) 

October 8, 2015

One side is a biotech company to develop new drugs and the other is a specialty pharma business.  The problem is that they have $50 million in cash and $75 million capitalization.  He thinks they will separate the companies.  It is worth $12 per share unless they hit it big in the drug side.

Pharma & Healthcare
0 0 0 0 0
0 comments

One side is a biotech company to develop new drugs and the other is a specialty pharma business.  The problem is that they have $50 million in cash and $75 million capitalization.  He thinks they will separate the companies.  It is worth $12 per share unless they hit it big in the drug side.

Pharma & Healthcare
0 0 0 0 0
0 comments
Fabrice Taylor

Publisher, The President's Club...

Price Price
$7.040
Owned Owned
Yes

COMMENT
Nuvo Research(NRI-T) 

January 28, 2015

A drug company that has a commercial product that is selling. Also has a very interesting allergy drug they are testing in Germany. If they can come up with a really effective treatment, this stock is going to go a lot higher. Results from phase 2 clinical trials are out in a week or 2. He has done extremely well in this name. Be a little bit cautious until you see what the clinical results are, but this is a classic case of “buy on rumour and sell on news”. Have a pile of cash so the downside is pretty limited. If it works out, the stock is going to go much higher, but if it doesn’t the downside could be $6 only.

Pharma & Healthcare
0 0 0 0 0
0 comments

A drug company that has a commercial product that is selling. Also has a very interesting allergy drug they are testing in Germany. If they can come up with a really effective treatment, this stock is going to go a lot higher. Results from phase 2 clinical trials are out in a week or 2. He has done extremely well in this name. Be a little bit cautious until you see what the clinical results are, but this is a classic case of “buy on rumour and sell on news”. Have a pile of cash so the downside is pretty limited. If it works out, the stock is going to go much higher, but if it doesn’t the downside could be $6 only.

Pharma & Healthcare
0 0 0 0 0
0 comments
Fabrice Taylor

Publisher, The President's Club...

Price Price
$9.640
Owned Owned
Yes

DON'T BUY
Nuvo Research(NRI-T) 

October 4, 2011

After he went to the AGM he decided he was not interested. They don’t manage to do what they say they are going to do. Can’t seem to gain traction. Concerned about a stock consolidation in the future.
Pharma & Healthcare
0 0 0 0 0
0 comments
After he went to the AGM he decided he was not interested. They don’t manage to do what they say they are going to do. Can’t seem to gain traction. Concerned about a stock consolidation in the future.
Pharma & Healthcare
0 0 0 0 0
0 comments
Benj Gallander

President, Contra the Heard Inv...

Price Price
$0.080
Owned Owned
No

DON'T BUY
Nuvo Research(NRI-T) 

January 26, 2009

(Market Call Minute.) Ranks 104 and will have difficulty performing.
Pharma & Healthcare
0 0 0 0 0
0 comments
(Market Call Minute.) Ranks 104 and will have difficulty performing.
Pharma & Healthcare
0 0 0 0 0
0 comments
Robert McWhirte

President, Selective Asset Mana...

Price Price
$0.130
Owned Owned
Unknown

BUY
Nuvo Research(NRI-T) 

January 12, 2007

Just got approval from the FDA to sell their arthritic medication. Likes this sector. The stock has built a base followed by a higher base over the last few years. This should be fine, but have stop at the higher base level.
Pharma & Healthcare
0 0 0 0 0
0 comments
Just got approval from the FDA to sell their arthritic medication. Likes this sector. The stock has built a base followed by a higher base over the last few years. This should be fine, but have stop at the higher base level.
Pharma & Healthcare
0 0 0 0 0
0 comments
Bill Carrigan

Technical , Getting Technical In...

Price Price
$0.630
Owned Owned
Unknown

WATCH
Nuvo Research(NRI-T) 

March 13, 2006

Estimates have been shaved back 10% in the past 90 days. Their work on arthritic drugs is interesting and phase 3 is looking good. They are watching it. If the drug is approved it would be positive for the company.
Pharma & Healthcare
0 0 0 0 0
0 comments
Estimates have been shaved back 10% in the past 90 days. Their work on arthritic drugs is interesting and phase 3 is looking good. They are watching it. If the drug is approved it would be positive for the company.
Pharma & Healthcare
0 0 0 0 0
0 comments
Robert McWhirte

President, Selective Asset Mana...

Price Price
$0.550
Owned Owned
No

Showing 1 to 8 of 8 entries
Successfully Saved Company
Successfully Saved Company